NASDAQ:CTIC CTI BioPharma (CTIC) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get CTI BioPharma alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About CTI BioPharma Stock (NASDAQ:CTIC)CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here CTIC Stock News HeadlinesMay 8, 2024 | uk.finance.yahoo.comQ1 2024 Veracyte Inc Earnings CallFebruary 22, 2024 | investing.comConnect Biopharma Holdings Ltd (CNTB)July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.December 16, 2023 | morningstar.comTheravance Biopharma Inc TBPHOctober 23, 2023 | uk.investing.comCTI Engineering Co Ltd (9621)August 23, 2023 | stockhouse.comSEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider TradingJune 27, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi completes acquisition of CTI BioPharma Corp.June 26, 2023 | finance.yahoo.comSobi completes acquisition of CTI BioPharma Corp.July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 7, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was upgraded to a Hold Rating at Stifel NicolausMay 30, 2023 | markets.businessinsider.comStifel Nicolaus upgrades CTI BioPharma (CTIC) to a HoldMay 25, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 25, 2023 | finance.yahoo.comSobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 24, 2023 | msn.comJMP Securities Maintains CTI BioPharma (CTIC) Market Perform RecommendationMay 24, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)May 16, 2023 | msn.comCTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go ThroughMay 16, 2023 | msn.comSVB Leerink Downgrades CTI BioPharma (CTIC)May 16, 2023 | markets.businessinsider.comSVB Securities downgrades CTI BioPharma (CTIC) to a HoldSee More Headlines Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Adam R. Craig M.B.A. (Age 57)M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director Comp: $1.09MMr. David H. Kirske (Age 69)Exec. VP, CFO & Sec. Comp: $590.41kMr. James K. Fong (Age 61)Exec. VP & Chief Commercial Officer Comp: $597.3kMr. Ed BellSr. Director of Investor RelationsMr. Bruce K. Bennett Jr. (Age 71)Sr. VP Global Pharmaceutical Operations Mr. John P. VolponeExec. VP & Chief of StaffDr. Jennifer A. SmithSr. VP of BiometricsMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCAltimmuneNASDAQ:ALTKamadaNASDAQ:KMDAParatek PharmaceuticalsNASDAQ:PRTKHookipa PharmaNASDAQ:HOOKView All Competitors CTIC Stock Analysis - Frequently Asked Questions How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to the consensus estimate of $24.88 million. When did CTI BioPharma's stock split? CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is James A. Bianco's approval rating as CTI BioPharma's CEO? 8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE) and SCYNEXIS (SCYX). This page (NASDAQ:CTIC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share CTI BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.